Truist Securities Reiterates Buy Rating on Procept BioRobotics Corp (PRCT)

Truist Securities analyst Richard Newitter reiterated a Buy rating and $70.00 price target on Procept BioRobotics Corp (NASDAQ: PRCT).

The analyst commented: "We believe gdce continues to leave room for upside given mgmt. commentary (a) it's trying to be conservative (still early in yr) (b) healthy March utilization momentum is carrying over into April/May, and (c) CFO Waters continues to emphasize a high degree of confidence on capital pipeline leads as well as increasingly predictable capital conversions (helped by more IDN placements). Mgmt. sees handpiece gdce continuing to set-up for beat & raises, and the decision to exercise “restraint”--- holding back a bigger initial raise following the 1Q handpiece upside---was made in this vein (to guide conservatively early in the year)."

For an analyst ratings summary and ratings history on Procept BioRobotics Corp click here. For more ratings news on Procept BioRobotics Corp click here.

Shares of Procept BioRobotics Corp closed at $59.02 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• AI/ML Innovations plans $2M private placement on the CSE
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating